Clinical Pharmacokinetics of Dasabuvir View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03-04

AUTHORS

Jennifer R. King, Jiuhong Zha, Amit Khatri, Sandeep Dutta, Rajeev M. Menon

ABSTRACT

Dasabuvir is a nonstructural (NS) 5B non-nucleoside inhibitor of the hepatitis C virus (HCV) used in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection. It is primarily metabolized by cytochrome P450 (CYP) 2C8, with a minor contribution from CYP3A. Biotransformation of dasabuvir forms the M1 metabolite, which retains antiviral activity. Dasabuvir exhibits linear pharmacokinetics with a terminal half-life of approximately 5–8 h, allowing for twice-daily dosing. The M1 metabolite of dasabuvir is the major metabolite in plasma and has a half-life similar to that of dasabuvir. Dasabuvir exposures in Asian subjects are comparable with Caucasian subjects. The pharmacokinetic characteristics of dasabuvir are similar between healthy subjects and HCV-infected patients, and are not appreciably altered by mild, moderate, or severe renal impairment or dialysis. Dasabuvir pharmacokinetic parameters were not significantly altered in subjects with mild or moderate hepatic impairment; however, exposures were significantly increased in subjects with severe hepatic impairment. Dasabuvir should be administered with food to maximize absorption. Coadministration of dasabuvir with a strong CYP2C8 inhibitor increased dasabuvir exposures by greater than tenfold, whereas coadministration with strong CYP3A inhibitors increased dasabuvir exposures by less than 50%. Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55–70%. Coadministration of dasabuvir with strong CYP2C8 inhibitors or strong CYP3A/CYP2C8 inducers is contraindicated. Results from several drug interaction studies demonstrated that dasabuvir in combination with ombitasvir/paritaprevir/ritonavir can be coadministered with most comedications that are commonly prescribed in HCV-infected patients. More... »

PAGES

1115-1124

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40262-017-0519-3

DOI

http://dx.doi.org/10.1007/s40262-017-0519-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084038494

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28258380


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "2-Naphthylamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uracil", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "King", 
        "givenName": "Jennifer R.", 
        "id": "sg:person.01021757231.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021757231.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zha", 
        "givenName": "Jiuhong", 
        "id": "sg:person.01134614621.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134614621.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khatri", 
        "givenName": "Amit", 
        "id": "sg:person.01166033042.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166033042.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dutta", 
        "givenName": "Sandeep", 
        "id": "sg:person.0617320041.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617320041.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Menon", 
        "givenName": "Rajeev M.", 
        "id": "sg:person.0704137621.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704137621.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40262-016-0373-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035600226", 
          "https://doi.org/10.1007/s40262-016-0373-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-016-0407-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037775753", 
          "https://doi.org/10.1007/s40261-016-0407-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-017-0518-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083859496", 
          "https://doi.org/10.1007/s40262-017-0518-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-016-0429-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034964681", 
          "https://doi.org/10.1007/s40262-016-0429-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-017-0520-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083888342", 
          "https://doi.org/10.1007/s40262-017-0520-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-015-0317-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038693879", 
          "https://doi.org/10.1007/s40262-015-0317-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13318-016-0341-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053197866", 
          "https://doi.org/10.1007/s13318-016-0341-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-04", 
    "datePublishedReg": "2017-03-04", 
    "description": "Dasabuvir is a nonstructural (NS) 5B non-nucleoside inhibitor of the hepatitis C virus (HCV) used in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection. It is primarily metabolized by cytochrome P450 (CYP) 2C8, with a minor contribution from CYP3A. Biotransformation of dasabuvir forms the M1 metabolite, which retains antiviral activity. Dasabuvir exhibits linear pharmacokinetics with a terminal half-life of approximately 5\u20138\u00a0h, allowing for twice-daily dosing. The M1 metabolite of dasabuvir is the major metabolite in plasma and has a half-life similar to that of dasabuvir. Dasabuvir exposures in Asian subjects are comparable with Caucasian subjects. The pharmacokinetic characteristics of dasabuvir are similar between healthy subjects and HCV-infected patients, and are not appreciably altered by mild, moderate, or severe renal impairment or dialysis. Dasabuvir pharmacokinetic parameters were not significantly altered in subjects with mild or moderate hepatic impairment; however, exposures were significantly increased in subjects with severe hepatic impairment. Dasabuvir should be administered with food to maximize absorption. Coadministration of dasabuvir with a strong CYP2C8 inhibitor increased dasabuvir exposures by greater than tenfold, whereas coadministration with strong CYP3A inhibitors increased dasabuvir exposures by less than 50%. Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55\u201370%. Coadministration of dasabuvir with strong CYP2C8 inhibitors or strong CYP3A/CYP2C8 inducers is contraindicated. Results from several drug interaction studies demonstrated that dasabuvir in combination with ombitasvir/paritaprevir/ritonavir can be coadministered with most comedications that are commonly prescribed in HCV-infected patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40262-017-0519-3", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "56"
      }
    ], 
    "keywords": [
      "hepatitis C virus", 
      "ombitasvir/paritaprevir/ritonavir", 
      "paritaprevir/ritonavir", 
      "strong CYP2C8 inhibitor", 
      "hepatic impairment", 
      "M1 metabolite", 
      "CYP2C8 inhibitors", 
      "moderate hepatic impairment", 
      "severe hepatic impairment", 
      "chronic HCV infection", 
      "twice-daily dosing", 
      "severe renal impairment", 
      "strong CYP3A inhibitors", 
      "drug interaction studies", 
      "cytochrome P450 2C8", 
      "HCV infection", 
      "renal impairment", 
      "CYP3A inhibitors", 
      "C virus", 
      "linear pharmacokinetics", 
      "Clinical Pharmacokinetics", 
      "dasabuvir", 
      "healthy subjects", 
      "CYP3A inducers", 
      "pharmacokinetic characteristics", 
      "non-nucleoside inhibitors", 
      "pharmacokinetic parameters", 
      "coadministration", 
      "Caucasian subjects", 
      "antiviral activity", 
      "Asian subjects", 
      "P450 2C8", 
      "major metabolite", 
      "impairment", 
      "ritonavir", 
      "patients", 
      "pharmacokinetics", 
      "inhibitors", 
      "exposure", 
      "subjects", 
      "metabolites", 
      "inducer", 
      "comedication", 
      "CYP3A.", 
      "dosing", 
      "infection", 
      "dialysis", 
      "virus", 
      "treatment", 
      "interaction studies", 
      "combination", 
      "food", 
      "plasma", 
      "activity", 
      "study", 
      "biotransformation", 
      "minor contribution", 
      "results", 
      "characteristics", 
      "form", 
      "absorption", 
      "parameters", 
      "contribution"
    ], 
    "name": "Clinical Pharmacokinetics of Dasabuvir", 
    "pagination": "1115-1124", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084038494"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40262-017-0519-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28258380"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40262-017-0519-3", 
      "https://app.dimensions.ai/details/publication/pub.1084038494"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_740.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40262-017-0519-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-017-0519-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-017-0519-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-017-0519-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-017-0519-3'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      106 URIs      91 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40262-017-0519-3 schema:about N2808a5f0b881441ca2d1c76e37460c13
2 N51c81da1b0f24b73b54d854a08c9e8fa
3 N56546dfc94cd4192adc29199a5bbae1f
4 N62120eb48fc1493085ddd68e50105e65
5 N689563d4b9d74c64a5ed7cc833b711cb
6 Na2a0655ff8fb482c9f80a555b7118a5f
7 Nb4cece1b2581477784311b6d6a66a4da
8 Ncf2f5b4457384cc1a49ef342f9a5a2a2
9 Ne31f4404408141c0ab2ce275ba622d31
10 Nf1572a5a58d24b00be1e79bc3c5e9cdb
11 Nfa4324fc61f4468c8d389c7900a097c5
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author N5ad2322649e84cd48b3f60383210702a
15 schema:citation sg:pub.10.1007/s13318-016-0341-6
16 sg:pub.10.1007/s40261-016-0407-x
17 sg:pub.10.1007/s40262-015-0317-8
18 sg:pub.10.1007/s40262-016-0373-8
19 sg:pub.10.1007/s40262-016-0429-9
20 sg:pub.10.1007/s40262-017-0518-4
21 sg:pub.10.1007/s40262-017-0520-x
22 schema:datePublished 2017-03-04
23 schema:datePublishedReg 2017-03-04
24 schema:description Dasabuvir is a nonstructural (NS) 5B non-nucleoside inhibitor of the hepatitis C virus (HCV) used in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection. It is primarily metabolized by cytochrome P450 (CYP) 2C8, with a minor contribution from CYP3A. Biotransformation of dasabuvir forms the M1 metabolite, which retains antiviral activity. Dasabuvir exhibits linear pharmacokinetics with a terminal half-life of approximately 5–8 h, allowing for twice-daily dosing. The M1 metabolite of dasabuvir is the major metabolite in plasma and has a half-life similar to that of dasabuvir. Dasabuvir exposures in Asian subjects are comparable with Caucasian subjects. The pharmacokinetic characteristics of dasabuvir are similar between healthy subjects and HCV-infected patients, and are not appreciably altered by mild, moderate, or severe renal impairment or dialysis. Dasabuvir pharmacokinetic parameters were not significantly altered in subjects with mild or moderate hepatic impairment; however, exposures were significantly increased in subjects with severe hepatic impairment. Dasabuvir should be administered with food to maximize absorption. Coadministration of dasabuvir with a strong CYP2C8 inhibitor increased dasabuvir exposures by greater than tenfold, whereas coadministration with strong CYP3A inhibitors increased dasabuvir exposures by less than 50%. Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55–70%. Coadministration of dasabuvir with strong CYP2C8 inhibitors or strong CYP3A/CYP2C8 inducers is contraindicated. Results from several drug interaction studies demonstrated that dasabuvir in combination with ombitasvir/paritaprevir/ritonavir can be coadministered with most comedications that are commonly prescribed in HCV-infected patients.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N02c471f851e64caf9fcfe4b83c82dfa4
28 N5a93fbf5a1df4186a01e62482e33049b
29 sg:journal.1085321
30 schema:keywords Asian subjects
31 C virus
32 CYP2C8 inhibitors
33 CYP3A inducers
34 CYP3A inhibitors
35 CYP3A.
36 Caucasian subjects
37 Clinical Pharmacokinetics
38 HCV infection
39 M1 metabolite
40 P450 2C8
41 absorption
42 activity
43 antiviral activity
44 biotransformation
45 characteristics
46 chronic HCV infection
47 coadministration
48 combination
49 comedication
50 contribution
51 cytochrome P450 2C8
52 dasabuvir
53 dialysis
54 dosing
55 drug interaction studies
56 exposure
57 food
58 form
59 healthy subjects
60 hepatic impairment
61 hepatitis C virus
62 impairment
63 inducer
64 infection
65 inhibitors
66 interaction studies
67 linear pharmacokinetics
68 major metabolite
69 metabolites
70 minor contribution
71 moderate hepatic impairment
72 non-nucleoside inhibitors
73 ombitasvir/paritaprevir/ritonavir
74 parameters
75 paritaprevir/ritonavir
76 patients
77 pharmacokinetic characteristics
78 pharmacokinetic parameters
79 pharmacokinetics
80 plasma
81 renal impairment
82 results
83 ritonavir
84 severe hepatic impairment
85 severe renal impairment
86 strong CYP2C8 inhibitor
87 strong CYP3A inhibitors
88 study
89 subjects
90 treatment
91 twice-daily dosing
92 virus
93 schema:name Clinical Pharmacokinetics of Dasabuvir
94 schema:pagination 1115-1124
95 schema:productId N48d6972bda454e06986f7b6e534954b7
96 N8b608bac692d488b8d00a8599f28dd75
97 Ne9be608b3b8141bc90598687b8910a8c
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084038494
99 https://doi.org/10.1007/s40262-017-0519-3
100 schema:sdDatePublished 2022-12-01T06:37
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N005a2c841cf045f590d08089c2189543
103 schema:url https://doi.org/10.1007/s40262-017-0519-3
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N005a2c841cf045f590d08089c2189543 schema:name Springer Nature - SN SciGraph project
108 rdf:type schema:Organization
109 N02c471f851e64caf9fcfe4b83c82dfa4 schema:issueNumber 10
110 rdf:type schema:PublicationIssue
111 N1cb5d93936de481ea42920691d35fda8 rdf:first sg:person.01134614621.49
112 rdf:rest Nc324edde3a724966bd0fdfeea3f882da
113 N2808a5f0b881441ca2d1c76e37460c13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antiviral Agents
115 rdf:type schema:DefinedTerm
116 N48d6972bda454e06986f7b6e534954b7 schema:name dimensions_id
117 schema:value pub.1084038494
118 rdf:type schema:PropertyValue
119 N51c81da1b0f24b73b54d854a08c9e8fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Humans
121 rdf:type schema:DefinedTerm
122 N56546dfc94cd4192adc29199a5bbae1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Sulfonamides
124 rdf:type schema:DefinedTerm
125 N5a93fbf5a1df4186a01e62482e33049b schema:volumeNumber 56
126 rdf:type schema:PublicationVolume
127 N5ad2322649e84cd48b3f60383210702a rdf:first sg:person.01021757231.40
128 rdf:rest N1cb5d93936de481ea42920691d35fda8
129 N62120eb48fc1493085ddd68e50105e65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name 2-Naphthylamine
131 rdf:type schema:DefinedTerm
132 N689563d4b9d74c64a5ed7cc833b711cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Uracil
134 rdf:type schema:DefinedTerm
135 N8b608bac692d488b8d00a8599f28dd75 schema:name doi
136 schema:value 10.1007/s40262-017-0519-3
137 rdf:type schema:PropertyValue
138 Na2a0655ff8fb482c9f80a555b7118a5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Drug Interactions
140 rdf:type schema:DefinedTerm
141 Nabe0687a33d34f5f9914f1c4d44f1c71 rdf:first sg:person.0704137621.30
142 rdf:rest rdf:nil
143 Nb4cece1b2581477784311b6d6a66a4da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Hepatitis C, Chronic
145 rdf:type schema:DefinedTerm
146 Nc324edde3a724966bd0fdfeea3f882da rdf:first sg:person.01166033042.78
147 rdf:rest Ne18939712f054574ab9f39462667b4b8
148 Ncf2f5b4457384cc1a49ef342f9a5a2a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Liver Diseases
150 rdf:type schema:DefinedTerm
151 Ne18939712f054574ab9f39462667b4b8 rdf:first sg:person.0617320041.33
152 rdf:rest Nabe0687a33d34f5f9914f1c4d44f1c71
153 Ne31f4404408141c0ab2ce275ba622d31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Hepacivirus
155 rdf:type schema:DefinedTerm
156 Ne9be608b3b8141bc90598687b8910a8c schema:name pubmed_id
157 schema:value 28258380
158 rdf:type schema:PropertyValue
159 Nf1572a5a58d24b00be1e79bc3c5e9cdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Drug Therapy, Combination
161 rdf:type schema:DefinedTerm
162 Nfa4324fc61f4468c8d389c7900a097c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Animals
164 rdf:type schema:DefinedTerm
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
169 schema:name Clinical Sciences
170 rdf:type schema:DefinedTerm
171 sg:journal.1085321 schema:issn 0312-5963
172 1179-1926
173 schema:name Clinical Pharmacokinetics
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01021757231.40 schema:affiliation grid-institutes:grid.431072.3
177 schema:familyName King
178 schema:givenName Jennifer R.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021757231.40
180 rdf:type schema:Person
181 sg:person.01134614621.49 schema:affiliation grid-institutes:grid.431072.3
182 schema:familyName Zha
183 schema:givenName Jiuhong
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134614621.49
185 rdf:type schema:Person
186 sg:person.01166033042.78 schema:affiliation grid-institutes:grid.431072.3
187 schema:familyName Khatri
188 schema:givenName Amit
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166033042.78
190 rdf:type schema:Person
191 sg:person.0617320041.33 schema:affiliation grid-institutes:grid.431072.3
192 schema:familyName Dutta
193 schema:givenName Sandeep
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617320041.33
195 rdf:type schema:Person
196 sg:person.0704137621.30 schema:affiliation grid-institutes:grid.431072.3
197 schema:familyName Menon
198 schema:givenName Rajeev M.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704137621.30
200 rdf:type schema:Person
201 sg:pub.10.1007/s13318-016-0341-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053197866
202 https://doi.org/10.1007/s13318-016-0341-6
203 rdf:type schema:CreativeWork
204 sg:pub.10.1007/s40261-016-0407-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037775753
205 https://doi.org/10.1007/s40261-016-0407-x
206 rdf:type schema:CreativeWork
207 sg:pub.10.1007/s40262-015-0317-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038693879
208 https://doi.org/10.1007/s40262-015-0317-8
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s40262-016-0373-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035600226
211 https://doi.org/10.1007/s40262-016-0373-8
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s40262-016-0429-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034964681
214 https://doi.org/10.1007/s40262-016-0429-9
215 rdf:type schema:CreativeWork
216 sg:pub.10.1007/s40262-017-0518-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083859496
217 https://doi.org/10.1007/s40262-017-0518-4
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/s40262-017-0520-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1083888342
220 https://doi.org/10.1007/s40262-017-0520-x
221 rdf:type schema:CreativeWork
222 grid-institutes:grid.431072.3 schema:alternateName Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA
223 schema:name Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, 60064, North Chicago, IL, USA
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...